Navigation Links
Widely used depression drug associated with dental implant failure
Date:9/3/2014

Alexandria, Va., USA The International and American Associations for Dental Research (IADR/AADR) have published a paper titled "SSRIs and the Risk of Osseointegrated Implant Failure A Cohort Study." Selective Serotonin Reuptake Inhibitors (SSRIs), the most widely used drugs for the treatment of depression, have been reported to reduce bone formation and increase the risk of bone fracture. Since osseointegration is influenced by bone metabolism, this study investigates the association between SSRIs and the risk of failures in osseointegrated implants. The manuscript, by researchers Khadijeh Al-Abedalla, Samer Abi Nader, Belinda Nicolau, Emad Rastikerdar, Faleh Tamimi and Xixi Wu, from McGill University, Montreal, Quebec, Canada; and Nach Daniel, from East Coast Oral Surgery, Moncton, New Brunswick, Canada, is published in the OnlineFirst portion of the IADR/AADR Journal of Dental Research (JDR).

This retrospective cohort study was conducted on patients treated with dental implants from January 2007 to January 2013. A total of 916 dental implants in 490 patients (94 implants on 51 patients using SSRIs) were used to estimate the risk of failure associated with the use of SSRIs. Data analysis involved cox proportional hazards, generalized estimating equations models and Kaplan-Meier analysis. After three to 67 months of follow-up, 38 dental implants failed and 784 succeeded in nonusers group while 10 failed and 84 succeeded in SSRIs-users group.

The primary outcome was that compared with non-users of SSRIs, SSRIs usage was associated with an increased risk of dental implants failure (HR= 2∙31; P< 0∙01). The failure rates were 4.6% for SSRI non-users and 10.6% SSRI users, respectively. The secondary outcomes were that small implant diameters (≤4mm) (P=0∙01), bone augmentation (P=0∙04) and smoking habits (P<0∙01) also seemed to be associated with higher risk of implant failure. The main limitation of this retrospective study was that drug compliance dose and treatment period could not be acquired from the files of the patients.

Within the limits of this study, these findings indicate that treatment with SSRIs is associated with an increased failure risk of osseointegrated implants. Please visit http://jdr.sagepub.com/content/early/recent for more information about this study or contact Ingrid L. Thomas at ithomas@iadr.org to request a PDF of the article.


'/>"/>

Contact: Ingrid L. Thomas
ithomas@iadr.org
703-299-8084
International & American Associations for Dental Research
Source:Eurekalert

Related medicine news :

1. Obstetric Complication Rates Vary Widely Between Hospitals in U.S.
2. Widely used drug no more effective than FDA approved medication in treating epileptic seizures
3. Prevalence of hepatitis C infection found to vary widely among Hispanics
4. Both real and sham acupuncture help ease side effects of widely used breast cancer drug
5. Potential for added medical benefits uncovered for widely used breast cancer drug
6. Gianluca Tognon Publishes Widely Read Blog Post Tackling 5 Lies Nutritionists Tell
7. Imprivata is the Most Widely Selected Single Sign-On Solution by U.S. Hospitals Using McKesson Paragon or Horizon According to HIMSS Analytics
8. Imprivata is the Most Widely Selected Single Sign-On Solution by U.S. Hospitals Using Siemens Soarian Clinicals according to HIMSS Analytics
9. Dehydration Widely Misunderstood, Reports Water and Health Researcher Sharon Kleyne
10. Jim Buck, Widely Considered the First Professional Dog Walker, Dies in NY at age 81
11. Rates of Serious Workplace Injuries Vary Widely by State, Allsup Reports in New Nationwide Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based ... In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. ... company had 800 customers and 2,250 RCEs at the time of acquisition. In ...
(Date:2/27/2017)... , ... February 27, 2017 , ... New Jersey ranks ... among all types and genders. And the need for advanced services is growing. ... its top-rated cancer care program, in collaboration with their non-profit partners in their fight ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... NuevaCare, a ... as diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important ... Bay Area consumers look for home care close to home, and by having city-specific ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ODH, Inc.™ ... Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director ... to use behavioral health analytics to improve Medicaid population health management. , ODH will ...
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017   Royal Philips (NYSE: ... in health technology, today announced 510(k) clearance from ... market its ElastQ Imaging capability, further expanding the ... ElastQ Imaging enables simultaneous imaging of tissue and ... the diagnosis of various liver conditions. With ElastQ ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... , Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) ... Adam Craig , M.D., Ph.D., as President and Chief Executive ... March 20, 2017. Dr. Craig succeeds Richard Love , ... the company,s Board of Directors.  Dr. Craig has over 20 ... both the US and Europe . ...
Breaking Medicine Technology: